0000000000336260

AUTHOR

Patricia Gassó

showing 3 related works from this author

jop-2017-3257-File006 – Supplemental material for Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients w…

2018

Supplemental material, jop-2017-3257-File006 for Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis by Patricia Gassó, Sergi Mas, Miquel Bioque, Bibiana Cabrera, Antonio Lobo, Ana González-Pinto, Covadonga M. Díaz-Caneja, Iluminada Corripio, Eduard Vieta, Josefina Castro-Fornieles, Salvador Sarró, Anna Mané, Julio Sanjuan, Adrián Llerena, Amalia Lafuente, Jerónimo Saiz-Ruiz, Miguel Bernardo and PEPs Group in Journal of Psychopharmacology

FOS: PsychologyFOS: Clinical medicine170199 Psychology not elsewhere classified110319 Psychiatry (incl. Psychotherapy)111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified110904 Neurology and Neuromuscular Diseases
researchProduct

Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis.

2018

Background: Hyperprolactinemia is a common side-effect of antipsychotics (APs), which may trigger serious secondary problems and compromise the adherence to treatment which is crucial for prognosis, especially in patients presenting with a first-episode of psychosis (FEP). Aims: We evaluated, in some cases for the first time, the effect of polymorphisms in multiple candidate genes on serum prolactin (PRL) levels in an AP-treated FEP cohort recruited in the multicenter PEPs study (Phenotype − genotype and environmental interaction; Application of a predictive model in first psychotic episodes). Methods: PRL concentration was measured in serum from 222 patients. A total of 167 polymorphisms w…

AdultMalePsychosismedicine.medical_specialtyCandidate geneSerotoninSide effectAdolescentmedicine.medical_treatmentDopaminePeptidyl-Dipeptidase A03 medical and health sciencesYoung Adult0302 clinical medicineDopaminePolymorphism (computer science)Internal medicinemedicineHumansReceptor trkBPharmacology (medical)AntipsychoticPharmacologyMembrane GlycoproteinsPolymorphism Geneticbusiness.industryReceptors Dopamine D2medicine.diseaseProlactin030227 psychiatryProlactinHyperprolactinemiaPsychiatry and Mental healthEndocrinologyPsychotic DisordersCohortFemalebusiness030217 neurology & neurosurgerymedicine.drugAntipsychotic AgentsJournal of psychopharmacology (Oxford, England)
researchProduct

jop-2017-3257-File005 – Supplemental material for Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients w…

2018

Supplemental material, jop-2017-3257-File005 for Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis by Patricia Gassó, Sergi Mas, Miquel Bioque, Bibiana Cabrera, Antonio Lobo, Ana González-Pinto, Covadonga M. Díaz-Caneja, Iluminada Corripio, Eduard Vieta, Josefina Castro-Fornieles, Salvador Sarró, Anna Mané, Julio Sanjuan, Adrián Llerena, Amalia Lafuente, Jerónimo Saiz-Ruiz, Miguel Bernardo and PEPs Group in Journal of Psychopharmacology

FOS: PsychologyFOS: Clinical medicine170199 Psychology not elsewhere classified110319 Psychiatry (incl. Psychotherapy)111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified110904 Neurology and Neuromuscular Diseases
researchProduct